Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 8 No. 1 (2004)

Mouse Models in Cardiology Research

  • Aasakiran Madamanchi
November 5, 2020




  1. Doevendans PA, J. Daemen M, de Muinck ED and Smits JF. Cardiovascular phenotyping in mice. Cardiovascular Research. 39: 34-49; 1998.
  2. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U S A. 89: 4471-44755; 1992.
  3. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471; 1992
  4. Navab M, Berliner JA, Watson AD et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:831-842; 1996.
  5. Heistad DD. Unstable coronary-artery plaques. N. Engl. J. Med.. 349:2285-2287; 2003.
  6. Daugherty A. Mouse models of atherosclerosis. Am. J. Med. Sci. 323: 3-10: 2002.
  7. Van den Maagdenberg AMJM, Frants RR et al. Transgenic mice carrying the apoliprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268:10540-10546;1993.
  8. Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front. Biosci. 6: D515-D5225; 2001.
  9. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893; 1993.
  10. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102: 130-135; 1998.
  11. Carmeliet P, Moons L, Stassen JM, et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am. J. Pathol. 150: 761-776, 1997.
  12. Chong PH, Cheng JW. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2. Ann Pharmacother. 38:845-852; 2004.
  13. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ. Res. 73: 792-796: 1993.
  14. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 77:701-712; 1994.
  15. Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 272:731-734; 1996.
  16. Pashmforoush M, Pomies P, Peterson KL, et al. Adult mice deficient in actinin-associated LIM-domain protein reveal a developmental pathway for right ventricular cardiomyopathy. Nat. Med. 7: 591-597; 2001
  17. Choi D-J, Koch WJ, Hunter JJ, Rockman HA. Mechanism for ß- adrenergic receptor desensitization in cardiac hypertrophy is increased ß-adrenergic receptor kinase. J. Biol. Chem. 272:17223-17229; 1997.
  18. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science. 268:1350-1353, 1995.
  19. Tevaearai HT, Eckhart AD, Walton GB, Keys JR, Wilson K, Koch WJ. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation. 106:124-129, 2002.
  20. Metzler B, Mair J, Lercher A, et al. Mouse model of myocardial remodelling after ischemia: role of intercellular adhesion molecule-1. Cardiovasc. Res. 49:399-407; 2001.
  21. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int. J. Cardiol. 58:95-117; 1997.
  22. Emanueli C, Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br J Pharmacol. 133:951-958; 2001.
  23. Doetschman T, Maeda N, Smithies O. Targeted mutation of the Hprt gene in mouse embryonic stem cells. Proc. Natl. Acad. Sci. U S A. 85:8583-8587; 1988.
  24. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation. 98: 1541- 1547; 1998.
  25. Pohost GM and Fuisz AR. From the microscope to the clinic : MR assessment of atherosclerotic plaque. Circulation. 98: 1477- 1478; 1998.
  26. James JF, Hewett TE and Robbins J. Cardiac physiology in transgenic mice. Circ Res. 82: 407-415; 1998.
  27. Hoit BD, Khoury SF, Kranias EG, Ball N and Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 77: 632-637; 1995.
  28. Knowles JW and Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 20: 2336-2345; 2000
  29. Huang W-Y, Aramburu J, Douglas PS and Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nature Medicine. 6: 482-483; 2000.
  30. Chu G, Haghighi K and Kranias EG. From mouse to man: Understanding heart failure through genetically altered mouse models. Journal of Cardiac Failure. 8: S432-S449; 2002.


Download data is not yet available.